Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Invivyd ( (IVVD) ) is now available.
On May 14, 2026, Invivyd reported first-quarter 2026 results showing PEMGARDA net product revenue of $13.7 million, a 22% increase over the prior-year period, and ending cash and cash equivalents of $184.2 million, supplemented by roughly $20 million raised via an at-the-market facility in April. Operating expenses rose quarter-over-quarter, largely due to spending on the pivotal DECLARATION trial for VYD2311, as the company continues commercial execution while preparing for a potential VYD2311 launch.
Clinically, Invivyd reported continued in vitro neutralizing activity for PEMGARDA and VYD2311 against the BA.3.2.2 (“Cicada”) SARS-CoV-2 variant and favorable safety-driven changes in the DECLARATION trial, including reduced post-dose monitoring time and relaxed enrollment and follow-up requirements. The company also completed full initial enrollment in DECLARATION in March 2026, upsized the study to bolster statistical power with top-line data now expected in the third quarter of 2026, aligned with the U.S. Food and Drug Administration on the pediatric DRUMMER study and the LIBERTY Phase 3 comparison against mRNA COVID vaccines, and laid plans for a Phase 2 trial of VYD2311 in Long COVID or vaccine-injury patients, reinforcing its strategic push to position monoclonal antibodies as a better-tolerated alternative to repeated vaccine boosters.
The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
The score is held back most by ongoing unprofitability and cash burn despite improving revenue and strong gross margins, with valuation also constrained by losses. Offsetting these are constructive clinical/commercial updates and a solid cash position highlighted on the earnings call and reinforced by subsequent corporate events, while technicals show only moderate momentum.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biotechnology company focused on developing monoclonal antibody therapies as vaccine alternatives and prophylactic treatments for COVID-19, targeting vulnerable populations for infectious disease prevention. Its lead commercial product is PEMGARDA (pemivibart), and its pipeline includes VYD2311, which is being advanced through pivotal, pediatric, and comparative trials to strengthen its position in the COVID-19 prevention market.
Average Trading Volume: 2,585,574
Technical Sentiment Signal: Sell
Current Market Cap: $421.4M
For detailed information about IVVD stock, go to TipRanks’ Stock Analysis page.